ArticleTheranostics2015

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.

Te-Wei Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.